Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

18.99 +5.30 (+38.71%)

Streaming Delayed Price Updated: 1:25 PM EST, Feb 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,543,373
Open	14.95
Bid (Size)	18.98 (100)
Ask (Size)	19.18 (300)
Prev. Close	13.69
Today's Range	14.61 - 20.35
52wk Range	12.56 - 25.00
Shares Outstanding	54,902,942
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

Today 12:30 EST

Via Chartmill

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

February 05, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Performance

YTD	+41.8%	+41.8%
1 Month	+29.4%	+29.4%
3 Month	+20.7%	+20.7%
6 Month	+29.0%	+29.0%
1 Year	-22.7%	-22.7%

More News

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

February 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

February 03, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

January 09, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

January 06, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

December 18, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

December 09, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

November 06, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences (PLSE) Earnings Transcript ↗

November 06, 2025

Via The Motley Fool

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

November 05, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

October 24, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

October 22, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 10, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 07, 2025

From Pulse Biosciences

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 17, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

September 10, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

September 08, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 04, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

September 02, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Frequently Asked Questions

Is Pulse Biosciences, Inc - Common Stock publicly traded?

Yes, Pulse Biosciences, Inc - Common Stock is publicly traded.

What exchange does Pulse Biosciences, Inc - Common Stock trade on?

Pulse Biosciences, Inc - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pulse Biosciences, Inc - Common Stock?

The ticker symbol for Pulse Biosciences, Inc - Common Stock is PLSE on the Nasdaq Stock Market

What is the current price of Pulse Biosciences, Inc - Common Stock?

The current price of Pulse Biosciences, Inc - Common Stock is 18.99

When was Pulse Biosciences, Inc - Common Stock last traded?

The last trade of Pulse Biosciences, Inc - Common Stock was at 02/06/26 01:25 PM ET

What is the market capitalization of Pulse Biosciences, Inc - Common Stock?

The market capitalization of Pulse Biosciences, Inc - Common Stock is 1.04B

How many shares of Pulse Biosciences, Inc - Common Stock are outstanding?

Pulse Biosciences, Inc - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.